# A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis

> **NCT03647228** · PHASE1 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 98 (actual)

## Conditions studied

- Healthy Subjects
- Cystic Fibrosis

## Interventions

- **DRUG:** IONIS-ENaCRx
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03647228
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-13
- **Primary completion:** 2020-10-13
- **Final completion:** 2020-10-13
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2021-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647228, "A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03647228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*